Table 2.
Published cases of CD4+CD56+ malignancies
| Authors | Year | n | Chemotherapy | Irradiation | CR/PR | Median survival |
|---|---|---|---|---|---|---|
| Adachi et al10 | 1994 | 1 | CHOP | No | 0/1 | 24 |
| Hayashi et al9 | 1994 | 1 | CHOP | Yes | 1/0 | 53 |
| Brody et al13 | 1995 | 1 | COP | No | 0/0 | 6.5 |
| Nakamura et al14 | 1995 | |||||
| Kobashi et al15 | 1996 | 3 | CAMBO-VIP (1), THPOC (1), CHOP+BMT (1) | ND | 3/0 | 17+ |
| Savilo et al16 | 1995 | 1 | RT | Yes | 1/0 | 22+ |
| Dummer et al17 | 1996 | 1 | IFN-α | Yes+PUVA | 0/0 | 17+ |
| Emile et al18 | 1996 | 2 | n.d. | ND | n.d. | 4 |
| DiGiuseppe et al19 | 1997 | 4 | Prednisone (2), COP+mitoxantrone (1), unknown (1) | No | 2/1 | 8 |
| Savoia et al12 | 1997 | 4 | CHOP (1), ACOP-B (1), P-VEBEC (1) | Yes (1) | 3/0 | 8 |
| Drénou et al20 | 1997 | 1 | CHOP+MTX, cytarabine, etoposide, allogeneic BMT | TBI | 1/0 | 14+ |
| Uchiyama et al21 | 1998 | 1 | IL-2 | Yes | 1/0 | 20 |
| Bagot et al22 | 1998 | 1 | COP+C | No | 1/0 | 16 |
| Kameoka et al23 | 1998 | 2 | CHOP (1), CHOP-like (1) | No | 1/0 | 8 |
| Bastian et al24 | 1998 | 1 | No | Yes | 1/0 | 18+ |
| Ko et al25 | 1998 | 1 | CHOP | No | 1/0 | 32+ |
| Petrella et al11 | 1999 | 7 | COP (1), CP (1), CVBM (1), CCVP (2), DC (1), LDC (1) | No | 7/0 | 17 |
| Mukai et al26 | 1999 | 1 | Cis-VACD autoPBSCT | No | 1/0 | 40 |
| Mhawech et al27 | 2000 | 1 | CHOP | No | 0/1 | ND |
| Nagatani et al28 | 2000 | 4 | ACOMP-B (19, COP (1), etoposide, prednisone, IFN-α/γ | Yes (1) | 1/2 | 12.5 |
| Falcão et al29 | 2000 | 3 | ALL-regimen (1) CHOP (2) | No | 1/0 | 3 |
| Kojima et al30 | 2000 | 1 | Cis-VACD (1) | TBI | 2/0 | 32.5 |
| Ginarte et al31 | 2000 | 1 | Cyclophosphamide, vincristine, MTX; i.th. MTX, hydrocortisone, cytarabine | No | 1/0 | 14+ |
| Rakozy et al32 | 2001 | 2 | CHOP (1) | No | 1/0 | 17.5 |
| Yamada et al33 | 2001 | 2 | Steroids and chemotherapy (1), CHOP (1) | Electron beam therapy (1) | 1/1 | 31 |
| Kimura et al34 | 2001 | 1 | ALL-regimen | ND | 1/0 | 13+ |
| Honda et al35 | 2001 | 1 | CHOP+sobuzoxane | No | 0/1 | ND |
| Alvarez-Larran et al36 | 2001 | 1 | CHOP | No | 1/0 | 18 |
| Kato et al37 | 2001 | 1 | CHOP+HD Dexa CCE, +autologous PBSCT | No | 1/0 | 13 |
| Aoyama et al 38 | 2001 | 1 | Vincristine, prednisone | No | 1/0 | 6 |
| Feuillard et al39 | 2002 | 21 | Multiple | No | 2/17 | 12 |
| Khoury et al40 | 2002 | 6 | CHOP (2), hyper-CVAD (1)+MTX, cytarabine (2), POMP (1) | Yes (1) | 7.5 | |
| Chen et al41 | 2002 | 1 | None | Yes | 1/0 | ND |
| Chang et al42 | 2002 | 1 | CHOP | Yes | 1/0 | 5+ |
| Bayerl et al43 | 2002 | 3 | CHOP (1) CHOP, ifosfamide, etoposide (1), cytarabine, daunorubicin (1) | No | 2/0 | 21+ |
| Petrella et al5 | 2002 | 7 | NA (1), DC+RT (1), mini-CEOP (1), ACVBP (1),AVDB (1), CEP (1), HU (1) | No | 3/0 | 8 |
ACOMP-B: ACOP-B+methotrexate; ACOP-B: doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; ACVBP: daunorubicin, cyclophosphamide, vincristine, bleomycin; prednisone, ALL: acute lymphoblastic leukaemia; AVDB: adriamycin, vincristine, daunorubicin, bleomycin; CAMBO-VIP: cyclophosphamide, doxorubicine, methotrexate, bleomycin, vincristine, etoposide, ifosfamide, prednisone; CCE: carboplatin, cyclophosphamide, etoposide; CEP: cyclophosphamide, eldisine, prednisolone; CHEP: cyclophosphamide, epirubicin, vincristine, prednisone; CHOP: cyclophosphamide, vincristine, doxorubicin, prednisone; Cis-VACD: cisplatin, vindesine, doxorubicin, cyclophosphamide, dexamethasone; CMi: cytarabine, mitoxantrone; COP: cyclophosphamide, vincristine, prednisone; COP-C: COP+ chlorambucil; CP: chlorambucil, prednisone; CVBM: cyclophosphamide, vindesine, bleomycin, mitoxantrone; DC: daunorubicin, cytarabine; HU: hydroxyurea; Hyper-CVAD: CHOP with hyperfractionated cyclophosphamide; IC: idarubicin, cytarabine; IFN-α: interferon-alpha; IFN-γ: interferon-gamma; IL-2: interleukin-2; i.th.: intrathecal; LAC: lomustine, adriamycin, cytarabine; LDC: DC+lomustine; Mini-CEOP: cyclophosphamide, etoposide, vincristine, prednisone; MTX: methotrexate; POMP: mercaptopurine, vincristine, prednisone; PUVA: psoralen plus ultraviolet A therapy; P-VEBEC: prednisone, vinblastine, epirubicin; bleomycin, etoposide, cyclophosphamide; methotrexate, RT: radiotherapy; THPCOP: cyclophosphamide, THP-doxorubicin, vincristine prednisolone; ND: not determined; CR: complete remission; PR: partial remission.